A detailed history of Allspring Global Investments Holdings, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 17,118 shares of TGTX stock, worth $514,395. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,118
Previous 18,313 6.53%
Holding current value
$514,395
Previous $325,000 23.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$17.21 - $25.28 $20,565 - $30,209
-1,195 Reduced 6.53%
17,118 $400,000
Q2 2024

Jul 26, 2024

BUY
$13.32 - $19.19 $223,256 - $321,643
16,761 Added 1079.96%
18,313 $325,000
Q1 2024

Apr 18, 2024

SELL
$13.02 - $21.3 $2,135 - $3,493
-164 Reduced 9.56%
1,552 $23,000
Q4 2023

Jan 25, 2024

SELL
$6.68 - $18.81 $94,395 - $265,804
-14,131 Reduced 89.17%
1,716 $29,000
Q3 2023

Oct 27, 2023

BUY
$8.36 - $26.5 $132,480 - $419,945
15,847 New
15,847 $132,000
Q2 2023

Jul 18, 2023

BUY
$15.48 - $35.0 $13.9 Million - $31.4 Million
896,867 Added 1124.63%
976,615 $24.3 Million
Q1 2023

Apr 13, 2023

BUY
$10.23 - $19.34 $749,726 - $1.42 Million
73,287 Added 1134.3%
79,748 $1.2 Million
Q4 2022

Jan 23, 2023

SELL
$5.01 - $11.83 $711 - $1,679
-142 Reduced 2.15%
6,461 $76.4 Million
Q3 2022

Oct 26, 2022

BUY
$4.57 - $8.4 $25,285 - $46,477
5,533 Added 517.1%
6,603 $39,000
Q2 2022

Jul 25, 2022

SELL
$3.74 - $10.66 $79,815 - $227,495
-21,341 Reduced 95.23%
1,070 $4,000
Q1 2022

May 02, 2022

SELL
$7.81 - $20.45 $10,785 - $28,241
-1,381 Reduced 5.8%
22,411 $213,000
Q4 2021

Jan 28, 2022

BUY
$15.2 - $35.51 $361,638 - $844,853
23,792 New
23,792 $452,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.37B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.